June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Longevinex® Observed to Improve AMD Clinical Dark Adaptation
Author Affiliations & Notes
  • Stuart P Richer
    Eye Clinic 112E, Capt James Lovell Fed Hlth Care Facility, North Chicago, Illinois, United States
    Family Medicine, RFUMS / Chicago Medical School , North Chicago, Illinois, United States
  • Lawrence Joseph Ulanski
    Eye Clinic 112E, Capt James Lovell Fed Hlth Care Facility, North Chicago, Illinois, United States
    Eye & Ear Infirmary , University of Illinois , Chicago, Illinois, United States
  • Anish Bhandari
    Family Medicine, RFUMS / Chicago Medical School , North Chicago, Illinois, United States
  • Natalia Popenko
    Family Medicine, RFUMS / Chicago Medical School , North Chicago, Illinois, United States
  • Footnotes
    Commercial Relationships   Stuart Richer, Longevinex Partners (R); Lawrence Ulanski, None; Anish Bhandari, None; Natalia Popenko, None
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1985. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Stuart P Richer, Lawrence Joseph Ulanski, Anish Bhandari, Natalia Popenko; Longevinex® Observed to Improve AMD Clinical Dark Adaptation. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1985.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Gradual deterioration of photoreceptor / RPE health in untreated and treated AMD patients is common, irrespective of AREDS I, II supplement risk reduction, or intra-vitreal anti-VEGF pharmacologic approaches. We evaluated the dark adaptation (DA) of atrophic AMD patients, a measure of photoreceptor / RPE health before and after Longevinex ®, prescribed under compassionate care clinical guidelines.

Methods : Baseline clinical DA threshold (log DB), time (min), and fixation (%) were taken for 8 consecutive patients with established atrophic AMD (n=16 eyes; 7 M / 1 F; ages 64 - 89 years), using the Maculogix® Adapt Dx, with best refractive correction. Following treatment with Longevinex® (Longevinex Partners, Las Vegas, NV) 1 capsule qd AM, DA was repeated at varying follow-up exams.

Results : All but 2 eyes improved in one or more of the 3 DA parameters , with 1 case showing improvement by retinal SD OCT. Expected vs. actual (worse/same/better) Chi Square, P =0.01.

Conclusions : The first cases of DA stability / improvement are consistent with previous beneficial effects of Longevinex® as well as putative enhanced choriocapillaris circulation. DA is the earliest functional AMD sign, and a prime candidate for “ AMD prevention” This work merits expansion to a controlled study.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×